Skip to main content
GutCited

Lactobacillus casei for Antibiotic-Associated Diarrhea (AAD)

C

Some evidence for AAD prevention in hospitalized elderly patients (PLACIDE trial was negative for primary outcome but showed trends).

<\/script>\n
`; }, get iframeSnippet() { const domain = 'gutcited.com'; const params = 'ingredient\u003Dlactobacillus\u002Dcasei\u0026condition\u003Dantibiotic\u002Dassociated\u002Ddiarrhea'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

C

The Bottom Line

Some evidence for AAD prevention in hospitalized elderly patients (PLACIDE trial was negative for primary outcome but showed trends).

Key Study Findings

In Vitro
Complex probiotics alleviate ampicillin-induced antibiotic-associated diarrhea in mice.
Dose: 4-strain probiotic mixture vs: Ampicillin-induced AAD model Outcome: Gut microbiota recovery and immune modulation Effect: None None

Population: Ampicillin-induced AAD mouse model

Meta-Analysis n=692
Which probiotic has the best effect on preventing Clostridium difficile-associated diarrhea? A systematic review and …
Dose: None vs: Control group Outcome: the incidence rates of AAD and CDAD, and … Effect: OR 0.39, None

Population: Diarrhea patients

Randomized Controlled Trial n=314 4.3 weeks Double-blind
Probiotic Yogurt for the Prevention of Antibiotic-associated Diarrhea in Adults: A Randomized Double-blind Placebo-controlled Trial.
Dose: None vs: Placebo Outcome: Bowel function Effect: None p=0.30

Population: None

Systematic Review n=228
Strain-Specificity and Disease-Specificity of Probiotic Efficacy: A Systematic Review and Meta-Analysis.
Dose: None vs: None Outcome: Diarrhea outcomes Effect: None None

Population: None

Controlled Clinical Trial n=32 4.3 weeks Open-label
Feasibility of a Lactobacillus casei Drink in the Intensive Care Unit for Prevention of Antibiotic …
Dose: 10 billion L. casei, 2 bottles/day vs: Contemporary matched controls Outcome: Safety, feasibility, AAD incidence Effect: None None

Population: ICU patients on antibiotics

Meta-Analysis n=9569
Comparative efficacy and tolerability of probiotics for antibiotic-associated diarrhea: Systematic review with network meta-analysis.
Dose: None vs: Placebo/no probiotic Outcome: Prevention of antibiotic-associated diarrhea Effect: LGG OR 0.28 (0.17-0.47) for AAD prevention None

Population: Patients on antibiotics

Key Statistics

3

Studies

500

Participants

Positive

C

Grade

Referenced Papers

F1000Research 2016 63 citations
Journal of clinical … 2011 432 citations
International journal of … 2000 181 citations

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Commonly Used Dosages

general:
1-10 billion CFU/day
aadprevention:
6.5 billion CFU/day (Shirota strain)
immunesupport:
10 billion CFU/day

Upper limit: Well-tolerated up to 20 billion CFU/day in clinical trials

Dosages Studied in Research

Dosage Duration Effect N
4-strain probiotic mixture -- Positive --
None -- Positive 692
None 4.3 weeks Neutral 314
None -- Mixed 228
10 billion L. casei, 2 bottles/day 4.3 weeks Positive 32
None -- Positive 9569
None -- Mixed --
None -- Positive --

Best taken: With or without food; consistent daily timing recommended

Safety & Side Effects

Reported Side Effects

  • Mild gas and bloating during initial use
  • Occasional loose stools
  • Rare dairy-related reactions in lactose-sensitive individuals
  • Very rare: bacteremia in immunocompromised individuals

Known Interactions

  • Antibiotics (may reduce probiotic viability; space dosing 2 hours apart)
  • Immunosuppressants (theoretical risk in immunocompromised patients)

Tolerable upper intake: Well-tolerated up to 20 billion CFU/day in clinical trials

Always consult your healthcare provider before starting any supplement.

Frequently Asked Questions

Does Lactobacillus casei help with Antibiotic-Associated Diarrhea (AAD)?
Based on 3 studies with 500 participants, there is limited but promising evidence that Lactobacillus casei may support Antibiotic-Associated Diarrhea (AAD) management. Our evidence grade is C (Some Evidence).
How much Lactobacillus casei should I take for Antibiotic-Associated Diarrhea (AAD)?
Studies have used various dosages. A commonly studied range is 1-10 billion CFU/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Lactobacillus casei?
Reported side effects may include Mild gas and bloating during initial use, Occasional loose stools, Rare dairy-related reactions in lactose-sensitive individuals, Very rare: bacteremia in immunocompromised individuals. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Lactobacillus casei and Antibiotic-Associated Diarrhea (AAD)?
We rate the evidence as Grade C (Some Evidence). This rating is based on 3 peer-reviewed studies with 500 total participants. The overall direction of effect is positive.

Related Evidence

Other ingredients for Antibiotic-Associated Diarrhea (AAD)

FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. The products and information on this website are not intended to diagnose, treat, cure, or prevent any disease. The evidence grades presented are based on our analysis of published peer-reviewed research and do not constitute medical advice. Always consult your healthcare provider before starting any supplement regimen.